DFS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiaosong Chen, Jiahui Huang, Haoting Shi, Juanying Zhu, Weizhu Wu, Guolin Ye, Qi He, Yong Shi, Anqin Zhang, Xiaohong Xie, Xiaodong Wang, Xiangjing Chen, Weili Wu, Jundong Wu, Zhian Li, Zhanwen Li, Yuechu Dai, Weili Ren, Qing Shao, Yongan Chen, Yong Zeng, Fengzhe Zhang, Shuwen Dong, Mark Daniel Pegram, Kunwei Shen
J Clin Oncol 44(3) 143-152
PURPOSE: To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05. RESULTS: A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97]; P = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98]; P = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94]; P = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0% v 37.8%) and thrombocytopenia (4.5% v 0%). Other grade 3 to 4 toxicities were comparable. CONCLUSION: Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.
4 个 Figure · 14 个 KM 面板
FIG 2. Kaplan-Meier analysis of (A) DFS, (B) DDFS, and (C) OS in ITT population. Stratified HRs and its 95% CI were reported with their corresponding stratified Log-rank P value. Cb, carboplatin; DFS, disease-free survival; DDFS, distant DFS; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel B
Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. Kaplan-Meier analysis of (A) disease-free survival, (B) distant disease-free survival, and (C) OS in PPS population. Stratified HRs and its 95% CI were reported. Cb, carboplatin; DDFS, distant DFS; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; OS, overall survival; PPS, per-protocol set.
FIG A2. · Panel A
Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel B
Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel C
Panel C 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. Kaplan-Meier plot of DFS curve stratified by (A) age at diagnosis and (B) HER2 status. HER2-low indicated tumors with HER2 IHC status 1+ to 2+. Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
FIG A3. · Panel A
Panel A 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. · Panel A_2
Panel A_2 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. · Panel B
Panel B 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. · Panel B_4
Panel B_4 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A5. DFS among HRR tested population. (A) BRCA mutated population; (B) BRCA wild-type population; (C) HRR-mutated population; (D) HRR wild-type population. HRR test was performance among 138 patients (17.6%). HR reported with 95% CI. Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; HRR, homologous recombination repair.
FIG A5. · Panel A
Panel A 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A5. · Panel A_2
Panel A_2 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A5. · Panel B
Panel B 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A5. · Panel B_4
Panel B_4 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。